Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials.
Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials.
复制标题
晚期胰腺癌的区域动脉内化疗与全身化疗：随机对照试验的系统回顾和荟萃分析
DOI：
10.1371/journal.pone.0040847
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Hao J
中科院分区：
文献类型：
--
作者：
Liu F;Tang Y;Sun J;Yuan Z;Li S;Sheng J;Ren H;Hao J
目的探讨局部动脉内化疗（RIAC）与全身化疗治疗III/IV期胰腺癌的疗效和安全性。方法使用PubMed、ISI、EMBASE、Cochrane Library、谷歌、中国科学期刊数据库（VIP）和中国知网（CNKI）电子数据库，对1960年至2010年12月31日期间发表的所有文献进行随机对照试验，并对接受局部动脉内化疗或全身化疗的晚期胰腺癌患者进行分析。数据由两位审稿人独立提取。根据I2统计量和Q检验评估异质性，使用固定效应或随机效应模型汇总优势比和相对风险。采用RevMan 5.0软件进行统计分析。结果在492篇文献中，6项随机对照试验纳入298例患者，符合纳入meta分析的标准。8例患者通过局部动脉内化疗（RIAC）达到完全缓解（CR），而没有患者通过全身化疗达到完全缓解。与全身化疗相比，RIAC患者的部分缓解（RR = 1.99, 95% CI: 1.50, 2.65； RIAC组为58.06%，全身治疗为29.37%）、临床获益（RR = 2.34, 95% CI: 1.84, 2.97； RAIC组为78.06%，全身治疗为29.37%）、总并发症发生率（RR = 0.72, 95% CI: 0.60, 0.87； RIAC组为49.03%，全身治疗为71.33%）、血液学副作用(RR = 0.76, 95% CI: 0.63, 0.91；RIAC组60.87%，全身治疗组85.71%)。RIAC的中位生存时间（5-21个月）长于全身化疗（2.7-14个月）。同样，RIAC的一年生存率（28.6% ~ 41.2%）高于全身化疗（0% ~ 12.9%）。结论局部动脉内化疗治疗晚期胰腺癌较全身化疗有效，并发症少。
Objective To investigate the efficacy and safety of regional intra-arterial chemotherapy (RIAC) versus systemic chemotherapy for stage III/IV pancreatic cancer. Methods Randomized controlled trials of patients with advanced pancreatic cancer treated by regional intra-arterial or systemic chemotherapy were identified using PubMed, ISI, EMBASE, Cochrane Library, Google, Chinese Scientific Journals Database (VIP), and China National Knowledge Infrastructure (CNKI) electronic databases, for all publications dated between 1960 and December 31, 2010. Data was independently extracted by two reviewers. Odds ratios and relative risks were pooled using either fixed- or random-effects models, depending on I2 statistic and Q test assessments of heterogeneity. Statistical analysis was performed using RevMan 5.0. Results Six randomized controlled trials comprised of 298 patients met the standards for inclusion in the meta-analysis, among 492 articles that were identified. Eight patients achieved complete remission (CR) with regional intra-arterial chemotherapy (RIAC), whereas no patients achieved CR with systemic chemotherapy. Compared with systemic chemotherapy, patients receiving RIAC had superior partial remissions (RR = 1.99, 95% CI: 1.50, 2.65; 58.06% with RIAC and 29.37% with systemic treatment), clinical benefits (RR = 2.34, 95% CI: 1.84, 2.97; 78.06% with RAIC and 29.37% with systemic treatment), total complication rates (RR = 0.72, 95% CI: 0.60, 0.87; 49.03% with RIAC and 71.33% with systemic treatment), and hematological side effects (RR = 0.76, 95% CI: 0.63, 0.91; 60.87% with RIAC and 85.71% with systemic treatment). The median survival time with RIAC (5–21 months) was longer than for systemic chemotherapy (2.7–14 months). Similarly, one year survival rates with RIAC (28.6%−41.2%) were higher than with systemic chemotherapy (0%−12.9%.). Conclusion Regional intra-arterial chemotherapy is more effective and has fewer complications than systemic chemotherapy for treating advanced pancreatic cancer.
登录
查看更多内容
影响因子：
3.8
作者：
Friess H;Langrehr JM;Oettle H;Raedle J;Niedergethmann M;Dittrich C;Hossfeld DK;Stöger H;Neyns B;Herzog P;Piedbois P;Dobrowolski F;Scheithauer W;Hawkins R;Katz F;Balcke P;Vermorken J;van Belle S;Davidson N;Esteve AA;Castellano D;Kleeff J;Tempia-Caliera AA;Kovar A;Nippgen J
通讯作者：
Nippgen J
影响因子：
45.3
作者：
Moore, Malcolm J.;Goldstein, David;Parulekar, Wendy
通讯作者：
Parulekar, Wendy
DOI：
10.1016/j.jvir.2009.09.027
发表时间：
2010-01-01
影响因子：
2.9
作者：
Tanaka, Toshihiro;Yamamoto, Kiyosei;Kichikawa, Kimihiko
通讯作者：
Kichikawa, Kimihiko
影响因子：
45.3
作者：
Burris, HA;Moore, MJ;VanHoff, DD
通讯作者：
VanHoff, DD
影响因子：
--
作者：
Bayraktar, Soley;Rocha-Lima, Caio M.
通讯作者：
Rocha-Lima, Caio M.